We focus on the development of novel medicines using our proprietary Extreme Genetics® platform.
We are a clinical-stage biopharmaceutical company discovering and developing a pipeline of differentiated therapeutics for orphan indications that we intend to commercialize on our own, and for larger market indications that we intend to partner with global pharmaceutical industry leaders. We have built a core platform, which we call Extreme Genetics®, enabling the discovery of validated drug targets by studying rare human diseases with extreme traits, including diseases caused by mutations in ion channels, known as channelopathies. Our integrated platform has a full complement of in-house capabilities for human genetics and small molecule drug discovery, and for pre-clinical and clinical development.
Shutting Down Pain
Xenon featured in Genentech’s Big Ideas animated short
September 24, 2015 – Xenon Pharmaceuticals Announces Initiation of XEN801 Phase 1 Clinical Trial – Phase 2 in Acne Patients Expected to be Initiated by Year-End
September 21, 2015 – Xenon Pharmaceuticals Achieves Milestone in Genentech Collaboration to Discover Novel Pain Targets
September 3, 2015 – Xenon Pharmaceuticals to Present at the 10th Annual Wells Fargo Healthcare Conference